Subscribe to “CTRI Bulletin”
Submit a paper

"CTRI Bulletin"
#1,(14),2021.

CTRI BULLETIN №1 (14) 2021

Journal Information: Read
Chief Editor: Ergeshov A.E.
Year of foundation: 2017
ISSN (Print): Browse
Publisher site: http://critub.ru
http://tb-bulletin.ru

Return to archive

CONTENT

1)

The specific features of iron metabolism in patients with pulmonary TB associated with HIV infection or diabetes mellitus

Abdullaev R.Yu., Komissarova O.G., Terentyeva O.R.

5 READ MORE
2)

Features of the course and outcomes of pregnancy in women with tuberculosis

Borodulina E.A., Kuzmina A.I.

15 READ MORE
3)

The influence of Oshanin onion extract (mountain Tajikistan) on the course of TB infection in experimental TB in inbred mice

Mirzoeva F.D., Averbakh M.M., Sterzhanova N.V., Satorov S.S., Nikonenko B.V.

21 READ MORE
4)

Comorbidity of the novel coronavirus infection (COVID-19) with TB and advanced stage HIV infection followed by immunodeficiency

Mishina A.V., Mishin V.Yu., Sobkin A.L., Sergeeva N.V., Osadchaya O.A., Pilipenko S.V., Epishin I.A.

28 READ MORE
5)

Pulmonary mycobacterioses in the megapolis: management, treatment outcomes, follow-up

Guntupova L.D., Borisov S.E.

38 READ MORE
6)

The comparison of radiological features of infiltrative and disseminated pulmonary TB in dynamics based on computed tomography and plain chest roentgenography results

Yatsukova A.V., Babaeva I.Yu., Shapolovsky V.S., Shapolovskaya A.S., Yatsukov A.V., Zhukova D.Yu.

50 READ MORE
7)

Chemotherapy in senior children and adolescents with drug-resistant pulmonary TB: new challenges – new solutions

Panova L.V., Ovsyankina E.S.

58 READ MORE
8)

The opportunities of cardioprotective therapy: patients with TB and chronic obstructive pulmonary disease in focus

Bagisheva N.V., Mordyk A.V., Moiseeva M.V., Nesterova K.I., Nebesnaya E.Yu., Filipenko G.V., Aroyan A.R., Batishcheva T.L., Andreeva I.A.

65 READ MORE
9)

Effectiveness and cost-effectiveness of mass fluorography screening of the population on the example of Sakha (Yakutia) Republic

Kravchenko A.F., Shepeleva L.P.

76 READ MORE
10)

Methods for the identification of Mycobacterium species

Larionova E.E., Andreevskaya S.N., Smirnova T.G., Sevastyanova E.V., Chernousova L.N.

87 READ MORE
11)

To the 70th anniversary of Alexander Solomonovich Apt

99  
     

THE SPECIFIC FEATURES OF IRON METABOLISM IN PATIENTS WITH PULMONARY TB ASSOCIATED WITH HIV INFECTION OR DIABETES MELLITUS

Article 1.Page 5.
ARTICLE TITLE:

THE SPECIFIC FEATURES OF IRON METABOLISM IN PATIENTS WITH PULMONARY TB ASSOCIATED WITH HIV INFECTION OR DIABETES MELLITUS

DOI: 10.7868/S2587667821010015

AUTORS:

Abdullaev R.Yu.1, Komissarova O.G.1, 2, Terentyeva O.R.1

1 Central TB Research Institute, Moscow, Russia

2 N.I. Pirogov Russian National Research Medical University, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 15.04.2020

The review provides literature data on the features of iron metabolism in patients with pulmonary TB, HIV-associated TB or comorbid TB and diabetes mellitus. A decrease in circulating iron in TB patients, including those with HIV- or diabetes-comorbidities, is a frequent component of the systemic inflammatory response and is aimed at distinguishing iron from an infectious pathogen and preventing its replication. At the same time, true iron deficiency may also cause a decrease in circulating iron.

The article was prepared in the framework of scientific research No. 0515-2015-0015 “Modern approaches to diagnosis, epidemiology and treatment of drug resistant pulmonary TB, including TB associated with HIV infection or diabetesmellitus”.

REFERENCES:
  1. Dvoretsky L.I. Algorithms for diagnosis and treatment of iron-deficiency anemia. Russian Medical Journal, 2002, vol. 10, no. 17, pp. 743–750. (In Russ.)
  2. Dolgov V.V., Lugovskaya S.A., Pochtar M.E. Laboratory diagnosis of iron metabolism disorders. Petersburg, Vital Diagnostics StP, 2002, 52 p. (In Russ.)
  3. Inyakova N.V., Demikhov V.G., Zhurina O.N. Anemia in tuberculous infection. Journal of postgraduate medical education, 2015, no. 3, pp. 74–81. (In Russ.)
  4. Kaminskaya G.O., Abdullaev R.Yu., Baturova G.A., Komissarova O.G. The peculiarities of iron status in pulmonary TB patients on treatment. Tuberculosis and Lung Diseases, 2009, vol. 86, no. 7, pp. 46–55. (In Russ.)
  5. Kaminskaya G.O., Abdullaev R.Yu., Baturova G.A., Komissarova O.G. The role of soluble transferrin re­ceptors in the detection of iron deficiencies in pul­monary TB patients. Tuberculosis and Lung Diseases, 2013, vol. 90, pp. 21–27. (In Russ.)
  6. Lukina E.A., Dezhenkova A.V. Iron metabolism in health and pathology. Klinicheskaya onkogematologiya, 2015, vol. 8, no. 4, pp. 355–361. (In Russ.)
  7. Pogorelov V.M., Kozinets G.I., Kovaleva L.G. Labora­tory and clinical diagnosis of anemia. Moscow: Medit­sinskoye informatsionnoye agentstvo, 2004, 73 p. (In Russ.)
  8. Al-Omar I.A., Oluboyede A.O. Serum ferritin and other iron parameters in patients with pulmonary tu­berculosis. Saudi Med. J., 2002, vol. 23, pp. 244–246.
  9. Andrew K.D., Wood R., Vogt M., Lawn S.D. Predic­tive value of anemia for tuberculosis in HIV-infected patients in sub-Saharan Africa: an indication for rou­tine microbiological investigation using new rapid assays. Acquir. Immune Defic. Syndr., 2014, vol. 66, pp. 33–40.
  10. de Benoist B., McLean Erin., Egli I., Cogswell M. Worldwide prevalence of anemia 1993–2005. WHO Global Database on Anaemia. Geneva, World Health Organization, 2008, 51 p.
  11. Blackwell J.M., Goswami T., Evans C.A., Sibthor­pe D., Papo N., White J.K., Searle S., Miller E.N., Pea­cock C.S., Mohammed H., Ibrahim M. SLC11A1 (for­merly NRAMP1) and disease resistance. Cell Microbiol., 2001, vol. 3, pp. 773–784.
  12. Boelaert J.R., Vandecasteele S.J., Appelbera R., Gor­deuk V.R. The effect of the host’s iron status on tuberculosis. Infect. Dis., 2007, vol. 195, no. 12, pp. 1745–1753.
  13. O’Brien M.E., Kupka R., Msamanga G.I., Saathoff E., Hunter D.J., Fawzi W.W. Anemia is an independent predictor of mortality and immunologic progres­sion of disease among women with HIV in Tanza­nia. Acquir. Immune. Defic. Syndr., 2005, vol. 40, pp. 219–225.
  14. Buskin S.E., Sullivan P.S. Anemia and its treatment and outcomes in persons infected with human im­munodeficiency virus. Transfusion, 2004, vol. 44, pp. 826–832.
  15. Cellier M.F., Courville P., Campion C. Nramp1 phago­cyte intracellular metal withdrawal defense. Infect., 2007, vol. 9, pp. 1662–1670.
  16. Das B.S., Devi U., Mohan Rao C., Srivastava V.K., Rath P.K., Das B.S. Effect of iron supplementation on mild to moderate anemia in pulmonary tuberculosis. J. Nutr., 2003, vol. 90, pp. 541–550.
  17. Devi U., Rao C.M., Srivastava V.K., Rath P.K., Das B.S. Effect of iron supplementation on mild to moderate anemia in pulmonary tuberculosis. J. Nutr., 2003, vol. 90, pp. 541–550.
  18. Ekiz C., Agaoglu L., Karakas Z., Gurel N., Yalcin I. The effect of iron deficiency anemia on the function of the immune system. J., 2005, vol. 5, pp. 579–583.
  19. Forbes J.R., Gros P. Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interac­tions. Trends Microbiol. 2001, vol. 9, pp. 397–403.
  20. Friis H., Gomo E., Nyazema N., Ndhlovu P., Krarup H., Madsen P.H., Michaelsen K.F. Iron, haptoglobin phe­notype, and HIV‑1 viral load: a cross-sectional study among pregnant Zimbabwean women. Acquir. Immune Defic. Syndr., 2003, vol. 33, pp. 74–81.
  21. Gangaidzo I.T., Moyo V.M., Mvundura E., Aggrey G., Murphree N.L., Khumalo H., Saungweme T., Kas­vosve I., Gomo Z.A., Rouault T., Boelaert J.R., Gor­deuk V.R. Association of pulmonary tuberculosis with increased dietary iron. Infect. Dis., 2001, vol. 184, pp. 936–939.
  22. Girelli D., Nemeth E., Swinkels D.W. Hepcidin in the diagnosis of iron disorders. Blood, 2016, vol. 127, pp. 2809–2814.
  23. Gomes M.S., Boelaert J.R., Appelberg R. Role of iron in experimental Mycobacterium avium infection. Clin. Virol., 2001, vol. 20, no. 3, pp.117–122.
  24. Gordeuk V.R., Onojobi G., Schneider M.F., Dawkins F.W., Delapenha R., Voloshin Y., Bacon M., Minkoff H., Levine A., Cohen M., Greenblatt R.M. The as­sociation of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica, 2006, vol. 91, pp. 739–743.
  25. Gordeuk V.R., Moyo V.M., Nouraie M., Gangaid­zo I.T., Murphree N.L., Gomo Z.A.R., Boelaert R., Weiss G. Circulating cytokines in pulmonary tuber­culosis according to HIV status and dietary iron con­tent. J. Tuberc. Lung Dis., 2009, vol. 13, no. 10, pp. 1267–1273.
  26. Hella J., Cercamondi C.I., Mhimbira F., Sasamalo M., Stoffel N., Zwahlen M., Bodmer Th., Gagneux S., Rei­ther K., Zimmermann M., Risch L., Fenner L. Anemia in tuberculosis cases and household controls from Tanzania: Contribution of disease, coinfections, and the role of hepcidin. PLoS ONE, 2018, vol. 13, no. 4, pp. e0195985.
  27. Isanaka S., Aboud S., Mugusi F., Bosch R.J., Wil­lett W.C., Spiegelman D., Duggan C., Fawzi W.W. Iron status predicts treatment failure and mortality in tuberculosis patients: A prospective cohort study from Dar es Salaam, Tanzania. PLoS ONE, 2012, vol. 7, no. 5, pp. e37350.
  28. Isanaka S., Mugusi F., Urassa W., Willett W.C., Bosch R.J., Villamor E., Spiegelman D., Duggan C., Fawzi W.W. Iron deficiency and anemia predict mor­tality in patients with tuberculosis. Nutrition, 2012, vol. 142, pp. 350–357.
  29. Johannessen A., Naman E., Ngowi B.J., Sandvik L., Matee M.I., Aglen H.E., Gundersen S.G., Bruun J.N. Predictors of mortality in HIV-infected patients start­ing antiretroviral therapy in a rural hospital in Tanza­nia. BMC Infect. Dis., 2008, vol. 8, no. 52, pp. 1–10.
  30. Johansson K.A., Robberstad B., Norheim O.F. Fur­ther benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy. AIDS Res. Ther., 2010, vol. 7, no. 3, pp. 2–9.
  31. Johnsona E.E., Wessling-ResnickbIron M. Metabo­lism and the innate immune response to infection. Microbes Infect., 2012, vol. 14, no. 3, pp. 207–216.
  32. Kassu A., Yabutani T., Mahmud Z.H., Mohammad A., Nguyen N., Huong B.T., Hailemariam G., Diro E., Ayele B., Wondmikun Y., Motonaka J., Ota F. Altera­tion in serum levels of trace elements in tuberculosis and HIV-infections. J. Clin. Nutr., 2006, vol. 60, pp. 580–586.
  33. Kerkhoff A.D., Meintjes G., Opie J., Vogt M., Jhil­meet N., Wood R., Lawn S.D. Anaemia in patients with HIV-associated TB: relative contributions of anaemia of chronic disease and iron deficiency. J. Tuberc. Lung Dis., 2016, vol. 20, pp. 193–201.
  34. Kumar N.P., Banurekha V.V., Nair D., Dolla Ch., Ku­maran P., Babu S. Modulation of iron status biomarkers in tuberculosis-diabetes co-morbidity. Tuberculo­sis (Edinb), 2018, vol. 108, pp. 127–135.
  35. Lee S.W., Kang Y.A., Yoon Y.S., Um S.W., Lee S.M., Yoo C.G., Kim Y.W., Han S.K., Shim Y.S., Yim J.J. The prevalence and evolution of anemia associated with tuberculosis. Korean Med. Sci., 2006, vol. 21, pp. 1028–1032.
  36. van Lettow M., West C.E., van der Meer J.W., Wieringa F.T., Semba R.D. Low plasma selenium concen­trations, high plasma human immunodeficiency virus load and high interleukin‑6 concentrations are risk factors associated with anemia in adults presenting with pulmonary tuberculosis in Zomba district, Ma­lawi. J. Clin. Nutr., 2005, vol. 59, pp. 526–532.
  37. Lounis N., Truffot-Pernot C., Grosset J., Gor­deuk V.R., Boelaert J.R. Iron and Mycobacterium tuberculosis infection. Clin.Virol., 2001, vol. 20, no. 3, pp. 123–126.
  38. Lundgren J.D., Mocroft A. Anemia and survival in hu­man immunodeficiency virus. Infect. Dis., 2003, vol. 37 (Suppl. 4), pp. S297-S303.
  39. McDermid J.M., Jaye A., Schim van der Loeff M.F., Todd J., Bates C., Austin S., Jeffries D., Awasana A.A., Whittlex A.A., Prentice A. Elevated iron status strong­ly predicts mortality in West African adults with HIV infection. Acquir. Immune. Defic. Syndr., 2007, vol. 46, pp. 498–507.
  40. Minchella P.A., Donkor S., McDermid J.M., Suther­land J.S. Complex anemia in tuberculosis: the need to consider causes and timing when designing inter­ventions. Infect. Dis., 2015, vol. 60, pp. 764–772.
  41. de Monye C., Karcher D.S., Boelaert J.R., Gordeuk V.R. Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS, 1999, vol. 13, pp. 375–380.
  42. Moore R.D., Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. Acquir. Immune Defic. Syndr., 2002, vol. 29, pp. 54–57.
  43. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL‑6 mediates hypofer­remia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Clin. Invest., 2004, vol. 113, pp. 1271–1276.
  44. Nemeth E., Tuttle M.S., Powelson J., Vaughn M.B., Donovan A., Ward D.M., Ganz T., Kaplan J. Hepci­din regulates cellular iron efflux by binding to ferro­portin and inducing its internalization. Science, 2004, vol. 306, pp. 2090–2093.
  45. Oppenheimer S.J. Iron and its relation to immuni­ty and infectious disease. Nutr., 2001, vol. 131, pp. S616-S633.
  46. Petraro P., Duggan C., Spiegelman D., Hertzmark E., Makubi A., Chalamilla G., Siril H., Sando D., Aboud S., Fawzi W.W. Determinants of anemia among human immunodeficiency virus-positive adults at care and treatment clinics in Dar es Salaam, Tanzania. J. Trop. Med. Hyg., 2016, vol. 94, no. 2, pp. 384–392.
  47. Pietrangelo A., Trautwein C. Mechanisms of disease: the role of hepcidin in iron homeostasis – implica­tions for hemochromatosis and other disorders. Clin. Pract. Gastroenterol. Hepatol., 2004, vol. 1, no. 1, pp. 39–45.
  48. Popa E.C., Cernat R.C. Iron status in pulmonary tu­berculosis. Respir. J., 2005, vol. 26, (Suppl. 49), pp. S427.
  49. Ratledge C. Iron, mycobacteria and tuberculosis. Tu­berculosis (Edinb), 2004, vol. 84, pp. 110–130.
  50. Schaible U.E., Collins H.L., Priem F., Kaufmann S.H. Correction of the iron overload defect in beta‑2-mi­croglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. Exp. Med., 2002, vol. 196, pp. 1507–1513.
  51. Semba R.D., Shah N., Klein R.S., Mayer K.H., Schuman P., Vlahov D. Prevalence and cumulative inci­dence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infect­ed and -uninfected women. Dial. Transplant., 2002, vol. 34, pр. 260–266.
  52. Smith R.E. Jr. The clinical and economic burden of anemia. J. Manag. Care, 2010, vol. 16 (Suppl. 1), pp. S59–S66.
  53. Taha D.A., Thanoon Imad A-J. Antioxidant Status, C-reactive protein and iron status in patients with pulmonary tuberculosis. SQU Med. J., 2010, vol. 10, pp. 361–369.
  54. Wessels G., Schaaf H.S., Beyers N., Gie R.P., Nel E., Donald P.R. Haematological abnormalities in chil­dren with tuberculosis. J. Trop. Pediatr., 1999, vol. 45, pp. 307–310.
KEYWORDS:

TB, HIV infection, diabetes mellitus, iron metabolism.

FOR CORRESPONDENCE: 

Central ТВ Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Rizvan Yu. Abdullaev, Doctor of Medical Sciences, Professor, Head of Department of Pathomorphology, Electron Microscopy and Biochemistry, Head of Biochemistry Laboratory

Tel.: +7 (499) 785-90-71

E-mail: rizvan0403@yandex.ru

Oksana G. Komissarova, Doctor of Medical Sciences, Deputy Director for Research and Treatment, Central TB Research Institute; Professor of Phthisiology Department, Medical Faculty, Russian National Research Medical University named after N.I. Pirogov

Tel.: +7 (903) 118-48-18

E-mail: oksana.komissarova.72@mail.ru

Olga R. Terentyeva, Correspondence Postgraduate

Tel.: +7 (499) 785-90-71

E-mail: terentevaor@mail.ru

FEATURES OF THE COURSE AND OUTCOMESOF PREGNANCY IN WOMEN WITH TUBERCULOSIS

Article 2.Page 15.
ARTICLE TITLE:

FEATURES OF THE COURSE AND OUTCOMESOF PREGNANCY IN WOMEN WITH TUBERCULOSIS

DOI: 10.7868/S2587667821010027

AUTORS:

Borodulina E.A., Kuzmina A.I.

Samara State Medical University, Samara, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 06.09.2020

 The review is devoted to the most topical issues of epidemiology, diagnosis, and treatment of tuberculosis in pregnancy. The introduction of new methods of early diagnosis of tuberculosis, the development of regulatory documents and programs to reduce the incidence of tuberculosis in pregnant women remains urgent.

REFERENCES:
  1. Borodulina E.A. Screening for TB infection. Modern recommendations. Allergologiya i immunologiya v pe­diatrii, 2017, vol. 49, no. 2, pp. 29–33. (In Russ.)
  2. Borodulina E.A., Borodulina E.V., Gladunova E.P., Vdo-ushkina E.S. Medical and sanitary characteristics of newly detected TB patients. Meditsinsky alyans, 2018, no. 3, pp. 41–46. (In Russ.)
  3. Vasilyeva I.A., Pokrovsky V.V., Aksenova V.I. et al. Federal clinical recommendations for diagnosis and management of TB in HIV-positive patients. Tver, Tri­ada, 2014, 56 p. (In Russ.)
  4. Goponyako S.V., Buinevich I.V., Butko S.V., Bondaren­ko V.N. Epidemiology of newly detected pulmonary TB in women of reproductive age. Problemy zdorovya i ekologii, 2017, vol. 53, no. 3, pp. 79–83. (In Russ.)
  5. Eremenko E.P., Borodulina E.A., Sergeeva I.A., Kud­lai D.A., Borodulin B.E. Recombinant in vitro test T-SPOT.TB as a screening method for early diagno­sis of TB infection. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 4, pp. 48–52. (In Russ.)
  6. Zimina V.N., Savitskaya N.G., Sheshelyakina N.N. The course of pregnancy, childbirth, and perinatal out­comes in women with HIV infection and active TB. Problemy tuberkulyoza i boleznei legkikh, 2014, vol. 91, no. 9, pp. 21–22. (In Russ.)
  7. Korneva N.V., Starshinova A.A., Ananyev S.M., Ovchinnikova Yu.E., Dobgalyuk I.F. Predictive factors for TB development in children with latent TB infection. Tuberculosis and Lung Diseases, 2016, vol. 94, no. 6, pp. 14–19. (In Russ.) DOI: 10.21292/2075‑1230‑2016‑94‑6‑14‑19
  8. Kravchenko E.N., Mordyk А.V., Valeeva G.A. et al. Favourable pregnancy outcome in women with tu­berculosis: myth or reality. Vrach, 2015, vol. 1, pp. 5–8. (In Russ.)
  9. Kulchavenya E.V., Reikhrud T.A. Tuberculosis and pregnancy. Meditsina i obrazovaniye v Sibiri, 2014, no. 6, pp. 1–6. (In Russ.)
  10. Mordyk A.V., Kravchenko E.N., Valeeva G.A., Puzy­reva L.V. Comparative analysis of the specific course of pregnancy in healthy women and those ill with pulmonary tuberculosis. Sibirsky meditsinsky zhurnal, 2014, vol. 125, no. 2, pp. 26–31. (In Russ.)
  11. Mordyk A.V., Puzyreva L.V., Valeeva G.A. Tuberculo­sis in pregnancy: is it possible to overcome negative tendencies. Medical Almanac, 2015, vol. 39, no. 4, pp. 72–75. (In Russ.)
  12. Nechaeva O.B. The epidemic situation of tuberculo­sis in the Russian Federation. Zamestitel glavnogo vra­cha, 2015, no. 7, pp. 17–23. (In Russ.)
  13. All-Russian Public Organization: Russian Society of Phthisiatricians. Federal clinical recommendation on prevention, diagnosis, and management of TB in HIV-infected patients. (In Russ.) http://roftb.ru/net­cat_files/doks2016/rec2016.pdf
  14. Pavlova M.V., Sapozhnikova N.V., Archakova L.I., Gavrikov P.V., Starshinova A.A., Zilber E.K. Features of the course and effectiveness of treatment of pulmonary TB in a pregnant woman. Tuberculosis and Lung Dis­eases, 2014, no. 3, pp. 67–71. (In Russ.) DOI: 10.2129 2/2075‑1230‑2014‑0‑3‑105‑106
  15. Puzyreva L.V., Mordyk A.V., Valeeva G.A. The effect of tuberculosis on the course of pregnancy and fe­tal development. Zemsky vrach, 2016, vol. 29–30, no. 1–2, pp. 22–26. (In Russ.)
  16. Obstetrics: national guidelines. 2nd revised and enlarged edition Ed. by G.M. Savelyeva. Moscow, GEOTAR-Media, 2019, 1080 p. (In Russ.)
  17. Starshinova A.A., Kudlai D.A., Dovgalyuk I.F., Basantsova N.Yu., Zinchenko Yu.S., Yablonsky P.K. Effi­cacy of new methods for tuberculosis infection im­munodiagnostics in the Russian Federation. Journal Pediatria named after G.N. Speransky, 2019, vol. 98, no. 4, pp. 229–235. (In Russ.)
  18. Yablonsky P.K. National clinical recom­mendations. Moscow, GEOTAR-Media, 2016, 240 p. (In Russ.)
  19. Centers for Disease Control and Prevention. Provi­sional CDC Guidelines for the use and safety moni­toring of bedaquiline fumarate (Sirturo) for the treat­ment of multidrug-resistant tuberculosis. MMWR Recomm. 2016, no. 62, pp. 1–12.
  20. Dennis E.M., Hao Y., Tamambang M. et al. Tuberculo­sis during pregnancy in the United States: Racial/eth­nic disparities in pregnancy complications and in-hos­pital death. PloS Оne, 2018, vol. 13, no. 3, pp. 1–11. DOI: 10.1371/journal.pone.0194836
  21. Jana N., Barik S., Arora N. Maternal and perinatal outcomes of tuberculosis during pregnancy and the postpartum period: a systematic review and meta-analysis: Maternal tuberculosis and undernutrition – an ominous combination for adverse maternal and perinatal outcomes. BJOG, 2017, vol. 124, no. 13, pp. 2018–2019. DOI: 10.1111/1471–0528.14804
  22. Jaspard M., Elefant-Amoura E., Melonio I. et al. Be­daquiline and linezolid for extensively drug-resis­tant tuberculosis in pregnant woman. Infect. Dis., 2017, vol. 23, no. 10, pp. 39–51. DOI: 10.3201/ eid2310.161398
  23. Khan M., Pillay T., Mudley J. et al. Pregnancy com­plicated by drug-resistant tuberculosis and HIV in Durban, South Africa. Infect. Dis., 2017, no. 75, pp. 1264–1269.
  24. Kodadhala V., Gudeta A., Zerihun A. et al. Postpar­tum tuberculosis: A diagnostic and therapeutic chal­lenge. Case Rep. Pulmonol., 2016, no. 6, pp. 1–6. DOI: 10.1155/2016/3793941
  25. McKenna L., Frick M., Lee C. et al. A community per­spective on the inclusion of pregnant women in tu­berculosis drug trials. Infect. Dis., 2017, vol. 65, no. 8, pp. 1383–1387. DOI: 10.1093/cid/cix533
  26. Onyambu C.K., Tharamba N.M. Screening for con­genital fetal anomalies in low risk pregnancy: the Kenyatta National Hospital experience. BMC Preg­nancy Childbirth, 2018, vol. 180, no. 18, pp. 1–9. DOI: 10.1186/s12884–018–1824-z
  27. Padmapriyadarsini C., Shri Vijay S., BalaYogendra et al. Multidrug resistant tuberculosis during pregnan­cy. Indian J. Tuberc., 2017, vol. 64, no. 1, pp. 63–64. DOI: 10.1016/j.ijtb.2016.09.018
  28. Raznatovska O.M., Shalmin O.S. Peculiarities of the course of pregnancy in women with chemoresis­tant tuberculosis (literature review). Zaporizhzhya medical journal, 2019, vol. 21, no. 5, pp. 691–696. DOI: 10.14739/2310–1210.2019.5.179473
  29. Schnippel K., Ndjeka N., Conradie F. et al. A call to action: Addressing the reproductive health needs of women with drug-resistant tuberculosis. Afr. Med. J., 2016, vol. 106, no. 4, pp. 30–31. DOI: 10.7196/SAMJ. 2016.v106i4.10205
  30. Shovkun L.A., Aksenova V.A., Kudlai D.A., Sary­chev A.M. The role of immunological tests in the diagnosis of tuberculosis infection in children with juvenile idiopathic arthritis (JIA). European Respiratory Journal, Supplement, 2018, vol. 62, no. 52, pp. 60–64. DOI: https://doi.org/10.1183/13993003.congress‑2018. PA2733
  31. Sobhy S., Babiker O., Kunst H. Authors’reply: Effec­tive strategies to improve maternal and perinatal outcomes for pregnant women with tuberculosis, especially those living in poverty, are urgently need­ed. BJOG Exchange, 2017, vol. 124, no. 13, p. 2019. DOI: 10.1111/1471–0528.14803
  32. World Health Organization. Global tuberculosis report 2017. Geneva, WHO, 2017.
  33. World Health Organization. Global tuberculosis re­port 2019. Geneva, WHO, 2019.
KEYWORDS:

tuberculosis, pregnancy, pregnancy outcomes, diagnosis, treatment.

FOR CORRESPONDENCE:

Samara State Medical University

89, Chapaevskaya St., 443099, Samara, Russia

Elena A. Borodulina, Doctor of Medical Sciences, Professor, Head, Phthisiology and Pulmonology Department

Tel.: +7 (846) 332‑57‑35

E-mail: borodulinbe@yandex.ru

Alina I. Kuzmina, Fifth-year Student, Treatment Faculty

Tel.: +7 (846) 332‑57‑35

E-mail: alina.cuzmina555@mail.ru

THE INFLUENCE OF OSHANIN ONION EXTRACT (MOUNTAIN TAJIKISTAN) ON THE COURSE OF TB INFECTIONIN EXPERIMENTAL TB IN INBRED MICE

Article 3.Page 21.
ARTICLE TITLE:

THE INFLUENCE OF OSHANIN ONION EXTRACT (MOUNTAIN TAJIKISTAN) ON THE COURSE OF TB INFECTIONIN EXPERIMENTAL TB IN INBRED MICE

DOI: 10.7868/S2587667821010039

AUTORS:

Mirzoeva F.D.1, Averbakh M.M.2, Sterzhanova N.V.2, Satorov S.S1., Nikonenko B.V.2

1 Tajik State Medical University named after Abuali Ibni Sino, Dushanbe, Tajikistan

2 Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 14.09.2020

The experiment investigated the effect of alcoholic extract of Oshanin onion from Tajikistan in combination with isoniazid on the course of TB infection. BALB/c inbred mice infected with M. tuberculosis H37Rv were treated with isoniazid in combination with Oshanin onion extract. As a result, in terms of the spleen weight, the mycobacterial load in the lungs and pulmonary pathology, the combination of isoniazid with Oshanin onion extract was more effective than onion extract or isoniazid alone.

The research was conducted under scientific research topic No. 0515-2019-0018: “The investigation of mechanisms of innate and adaptive components of the immune response in tuberculosis and interstitial lung diseases”.

REFERENCES:
  1. Anywar G., Kakudidi E., Byamukama R.J., Mukon­zo R.J., Schubert A., Oryem-Origa H. Indigenous tradi­tional knowledge of medicinal plants used by herbal­ists in treating opportunistic infections among people living with HIV/AIDS in Uganda. Ethnopharm., 2020, vol. 246, no. 10, p. 112205. DOI: doi.org/10.1016/j. jep.2019.112205
  2. Bakal S.N., Bereswill S., Heimesaat M.M. Finding novel antibiotic substances from medicinal plants – Antimicrobial properties of Nigella sativa directed against multidrug resistant bacteria. J. Microbiol. and Immunol., 2017, vol. 7, no. 1, pp. 92–98.
  3. Hossan M.S., Jindal H., Maisha S., Samudi Raju C., Devi Sekaran S., Nissapatorn V., Kaharudin F., Su Yi L., Khoo T.J., Rahmatullah M., Wiart C. Antibacteri­al effects of 18 medicinal plants used by the Khyang tribe in Bangladesh. Pharm Biol., 2018, vol. 56, no. 1, pp. 201–208. DOI: 10.1080/13880209.2018.1446030
  4. Nikonenko B.V., Samala R., Einck L., Nacy C.A. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Agents Chemother., 2004, vol. 48, no. 12, pp. 4550–4555. DOI: 10.1128/AAC.48.12.4550–4555.2004
  5. Nuermberger E.L., Yoshimatsu T., Tyagi S., Williams K., Rosenthal I., O’Brien R.J., Vernon A.A., Chaisson R.E., Bishai and Grosset W.R. Moxifloxacin-containing regi­mens of reduced duration produce a stable cure in murine tuberculosis. J. Respir. Crit. Care Med., 2004, vol. 170, pp. 1131–1134. DOI: doi.org/10.1164/ rccm.200407-885OC
  6. Perlin D.S. Mechanisms of echinocandin antifungal drug resistance. NY Acad. Sci., 2015, vol. 1354, no. 1, pp. 1–11. DOI: doi.org/10.1111/nyas.12831
  7. Peterson E., Kaur P. Antibiotic resistance mecha­nisms in bacteria: relationships between resistance determinants of antibiotic producers, environmen­tal bacteria, and clinical pathogens. Frontiers in Mi­crobiology, 2018, vol. 9, Article 2928. DOI: 10.3389/ fmicb.2018.02928
  8. Pinkie C., Sheela D. Antimicrobial activity of Ama­ranth Alkaloid against pathogenic microbes. J. Herbal Medicine, 2016, vol. 4, no. 5, pp. 70–72.
  9. Pradipta I.S., Forsman L.D., Bruchfeld J., Hak E., Alffenaar J.W. Risk factors of multidrug-resistant tuber­culosis: A global systematic review and meta-analysis. Infect., 2018, vol. 77, no. 6, pp. 469–478. DOI: doi.org/10.1016/j.jinf.2018.10.004
KEYWORDS:

tuberculosis, Mycobacterium tuberculosis, treatment, inbred mice, onion extract.

FOR CORRESPONDENCE:

Tajik State Medical University named after Abuali Ibni Sino

139, Rudaki pr., 734000, Dushanbe, Republic of Tajikistan

Fazila D. Mirzoeva, Assistant, Department of Microbiology, Immunology and Virology

Tel.: (+992) 37‑224‑36‑87

Е-mail: fazila.mirzoeva88@mail.ru

Saidbek S. Satorov, Doctor of Medical Sciences, Professor, Head, Department of Microbiology, Immunology and Virology

Tel.: (+992) 37‑224‑36‑87

Е-mail: somona@tajmedun.tj

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Natalia V. Sterzhanova, Postgraduate, Immunogenetics Laboratory, Immunology Department

Tel.: +7 (965)148‑20‑32

Е-mail: sterghanova@gmail.com

Boris V. Nikonenko, Doctor of Medical Sciences, Leading Researcher, Immunogenetics Laboratory, Immunology Department

Tel.: +7(499) 785‑90‑72

Е-mail: boris.nikonenko52@gmail.com

Mikhail M. Averbakh, Doctor of Medical Sciences, Principal Researcher, Immunology Department

Tel.: +7 (916) 062‑30‑36

Е-mail: amm50@mail.ru

СOMORBIDITY OF THE NOVEL CORONAVIRUS INFECTION (COVID‑19) WITH TB AND ADVANCED STAGE HIV INFECTION FOLLOWED BY IMMUNODEFICIENCY

Article 4.Page 28.
ARTICLE TITLE:

СOMORBIDITY OF THE NOVEL CORONAVIRUS INFECTION (COVID‑19) WITH TB AND ADVANCED STAGE HIV INFECTION FOLLOWED BY IMMUNODEFICIENCY

DOI: 10.7868/S2587667821010040

AUTORS:

Mishina A.V.1, 3, Mishin V.Yu.1, 2, 3, Sobkin A.L.3, Sergeeva N.V.3,Osadchaya O.A.3, Pilipenko S.V.3, Epishin I.A.1

1 A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia

2 Central TB Research Institute, Moscow, Russia

3 TB Clinical Hospital No. 3 named after Prof. G.A. Zakharyin, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 25.10.2020

Aim: To investigate features of social status, clinical presentations, and diagnosis in TB patients with advanced stage HIV infection followed by immunodeficiency and the disease caused by the novel coronavirus infection COVID‑19 (SARS-Cov‑2) compared to patients with similar conditions without COVID‑19.

Materials and methods. We examined 20 TB/HIV patients with COVID‑19 (main group) and 20 patients with similar conditions without COVID‑19 (comparison group).

Results. Patients with TB/HIV comorbidity and the novel coronavirus infections were characterized by social disadvantage, drug abuse, concomitant hepatitis B or C virus, COPD, which was similar for the comparison group. It is impossible to differentiate between the diseases only based on clinical or radiological presentations. Thus, it is imperative to perform specialized microbiological and molecular genetic studies of specimens from the respiratory tract and other organs.

Conclusion. To protect the population from the SARS-CoV‑2 infection we should implement active screening of all TB/HIV patients registered by HIV centres or TB dispensaries.

REFERENCES:
  1. HIV infection and AIDS. National guidelines. Ed. by V.V. Pokrovsky. 4th revised and enlarged edition. Moscow, Geotar-Media, 2019, 156 p. (In Russ.)
  2. HIV infection in adults. Clinical recommendations ap­proved by the Ministry of Health of the Russian Fed­eration. National Association of experts in the pre­vention, diagnosis and treatment of HIV infection, 2019, 517 p. (In Russ.) https://lunaids.org/wp-content/ uploads/2020/01/Klinicheskie-rekomendaczii-VICH-infekcziya-u-vzroslyh‑2019-god.pdf
  3. Community-acquired pneumonia ICD‑10: J13-J18. Clinical recommendations by the Russian Respirato­ry Society (RRS) and the Interregional Association for Clinical Microbiology and Antimicrobial Chemothera­py (IACMAC), 2018, 88 p. (In Russ.) http://topuch.ru/ vnebolenichnaya-pnevmoniya-mkb‑10-j13-j18/index. html
  4. Temporary methodical recommendations by the Min­istry of Health of the Russian Federation. Prevention, diagnosis and treatment of the novel coronavirus in­fection (COVID‑19). Version 9 (26.10.2020), 235 p. (In Russ.)
  5. Temporary methodical recommendations on TB care in the context of the novel coronavirus infection (COVID‑19). All-Russian Public Organization “Russian Society of Phthisiatricians”, 2020, 46 p. (In Russ.)
  6. Mishina A.V., Mishin V.Yu., Sobkin A.L., Osadchaya O.A. Disseminated and generalized pulmonary TB and op­portunistic diseases in late-stage HIV infection with immunosuppression. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 12, pp. 68–70. (In Russ.) https://doi. org/10.21292/2075‑1230‑2018‑96‑12‑68‑70
  7. Mishina A.V., Mishin V.Yu., Ergeshov A.E., Romanov V.V. Disseminated lung lesions in patients with late-stage HIV disease with immunosuppression. CTRI Bulletin, 2019, no. 4, pp. 14–29. (In Russ.) https://doi. 10.7868/ S25877667819040022
  8. Federal clinical recommendations for TB diagnosis and treatment in HIV-infected patients. Moscow- Tver, Triada, 2014, 56 p. (In Russ.)
  9. Bartlett J., Gallant J., Fam P. Clinical aspects of HIV in­fection. Moscow, R. Valenta, 2012, 528 p. (In Russ.)
  10. Blanco J., Ambrosioni J., Garcia F., Martínez E., So­riano A., Mallolas J., Miro J.M. COVID‑19 in HIV in­vestigators. COVID‑19 in patients with HIV: clinical case series. Lancet HIV, 2020, Apr 15, pii: S2352– 3018 (20) 30111‑9.
  11. Docherty A.B., Harrison E.M., Green C.A., Hard­wick H.E., Pius R., Norman L., Holden K.A., Read M., Dondelinger F., Carson G., Merson L., Lee J., Plotkin D., Sigfrid L., Halpin S., Jackson C., Gamble C., Horby P.W., Nguyen-Van-Tam J.S., Dun­ning J., Openshaw P.J.M., Baillie J.K., Semple M.G. Features of 16,749 hospitalised UK patients with COVID‑19 using the ISARIC WHO clinical charac­terization protocol. medRxiv preprint https://doi. org/10.1101/2020.04.23.20076042
  12. Gervasoni C., Meraviglia P., Riva A., Giacomelli A., Oreni L., Minisci D., Atzori C., Ridolfo A., Cattaneo D. Clinical features and outcomes of HIV patients with coronavirus disease 2019. Infect. Dis., 2020, May 14, pii: ciaa579. https://doi.10.1093/cid/ciaa579 [Epub ahead of print].
  13. Guo W., Ming F., Dong Yu., Zhang Q., Zhang X., Ping­zheng Mo., Yong F., Liang Ke. A survey for COVID‑19 among HIV/AIDS patients in two districts of Wuhan. The Lancet. D‑20–02926. China-Manuscript. Draft- Manuscript. https://doi:10.2139/ssrn.3550029
  14. Hä rter G., Spinner C.D., Roider J., Bickel M., Krznaric I., Grunwald S., Schabaz F., Gillor D., Postel N., Mueller M.C., Müller M., Römer K., Schewe K., Hoff­mann C. COVID‑19 in people living with human im­munodeficiency virus: a case series of 33 patients. Infection. 2020, May 11. https://doi.10.1007/s15010- 020-01438-z [Epub ahead of print].
  15. Karmen-Tuohy S., Carlucci P.M., Zacharioudakis I.M., Zervou F.N., Rebick G., Klein E., Reich J., Jones S., Rahimian J. Outcomes among HIV-positive patients hospitalized with COVID‑19. medRxiv. https://www. medrxiv.org/content/10.1101/2020.05.07.20094797v1 [This preprint report has not been peer-reviewed].
  16. Panel on opportunistic infections in HIV-infected adults and adolescents. Guidelines for the preven­tion and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medi­cine Association of the Infectious Diseases Society of America. Chapter “Bacterial Respiratory Disease”, 2014, pp. 97–109. https://aidsinfo.nih.gov/guidelines/ html/4/adult-and-adolescent-oi-prevention-and-treat­ment-guidelines/327/bacterial-respiratory
  17. Wu Q., Chen T., Zhang H. Recovery from COVID‑19 in two patients with coexisted HIV infection. Med. Virol., 2020, May 13. https://doi.10.1002/jmv.26006. [Epub ahead of print].
KEYWORDS:

multidrug-resistant tuberculosis, MDR-TB, predictors of mortality, mortality among TB patients.

FOR CORRESPONDENCE:

A.I. Evdokimov Moscow State University of Medicine and Dentistry

20/1, Delegatskaya ul., 127473, Moscow, Russia

TB Clinical Hospital No. 3 named after Prof. G.A. Zakharyin

29, Kurkinskoye highway, 125466, Moscow, Russia

Anastasia V. Mishina, Candidate of Medical Sciences, Docent, Phthisiology and Pulmonology Department; Physician, TB/HIV Department

Tel.: +7 (910) 459‑18‑90

E-mail: av.mishina@yandex.ru

A.I. Evdokimov Moscow State University of Medicine and Dentistry

20/1, Delegatskaya ul., 127473, Moscow, Russia

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

TB Clinical Hospital No. 3 named after Prof. G.A. Zakharyin

29, Kurkinskoye highway, 125466, Moscow, Russia

Vladimir Yu. Mishin, Doctor of Medical Sciences, Professor, Head, Phthisiology and Pulmonology Department; Principal Researcher, Phthisiology Department

Tel.: +7 (910) 436‑56‑88

E-mail: mishin.vy@mail.ru

TB Clinical Hospital No. 3 named after Prof. G.A. Zakharyin

29, Kurkinskoye highway, 125466, Moscow, Russia

Alexander L. Sobkin, Candidate of Medical Sciences, Chief Physician

Tel.: +7 (495) 572‑71‑45

E-mail: Tkb_3@mail.ru

Natalia V. Sergeeva, Head, TB/HIV Department

Tel.: +7 (916) 178‑51‑60

E-mail: Tkb_3@mail.ru

Olga A. Osadchaya, Candidate of Medical Sciences, Head, Radiology Department

Tel.: +7 (901) 380‑10‑75

E-mail: Tkb_3@mail.ru

Svetlana V. Pilipenko, Physician, TB/HIV Department

Tel.: +7 (929) 586‑90‑28

E-mail: Tkb_3@mail.ru

A.I. Evdokimov Moscow State University of Medicine and Dentistry

20/1, Delegatskaya ul., 127473, Moscow, Russia

Ivan A. Epishin, Assistant, Phthisiology and Pulmonology Department

Tel.: +7 (999) 678‑26‑69

E-mail: brakozar@rambler.ru

PULMONARY MYCOBACTERIOSES IN THE MEGAPOLIS: MANAGEMENT, TREATMENT OUTCOMES, FOLLOW-UP

Article 5.Page 38.
ARTICLE TITLE:

PULMONARY MYCOBACTERIOSES IN THE MEGAPOLIS: MANAGEMENT, TREATMENT OUTCOMES, FOLLOW-UP

DOI: 10.7868/S2587667821010052

AUTORS:

Guntupova L.D., Borisov S.E.

Moscow Research and Clinical Center for Tuberculosis Control of Moscow Government Department of Health,Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 30.11.2020

We carried out retro- and prospective studies of 165 mycobacteriosis patients in 2004–2018 in order to improve management of this condition. We carried out a detailed study of drug resistance of nontuberculous mycobacteria (NTM) to systematize etiotropic therapies, and we discovered a wide variability of drug resistance spectra. We administered chemotherapy regimens based on the cluster analysis. We involved surgery in the complex management of mycobacteriosis. Treatment outcomes depended on some clinical parameters, and the chronic nature of mycobacterial inflammation preconditioned long, sometimes lifelong, follow-up of such patients.

REFERENCES:
  1. Eliseev P.I., Maryandyshev A.O., Tarasova I.V., Khel­dal A., Khinderaker S.G. Diagnosis and treatment of pulmonary mycobacteriosis in patients with suspect­ed pulmonary TB. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 7, pp. 61–62. (In Russ.)
  2. Otten T.F., Vasilyev A.V. Mycobacteriosis. St. Peters­burg: Med. pressa, 2005, 224 p. (In Russ.)
  3. Perelman M.I. National guidelines. Phthisiology. Mos­cow, GEOTAR-Media, 2007, pp. 75–91. (In Russ.)
  4. Petrova L.V., Melnikova E.I., Solovyev Yu.A., Lariono­va E.E., Sevastyanova E.V. Detection of nontubercu­lous mycobacteria in the Mari El Republic. Tuberculo­sis and Lung Diseases, 2018, vol. 96, no. 2, pp. 41–46. (In Russ.)
  5. Surkova L.K., Sagalchik E.R., Borisenko T.D., Zalutska­ya O.M. Prevalence of nontuberculous mycobacteria, challenges in diagnosis and treatment of mycobac­terioses. Vesti natsionalnoi akademii nauk Belarusi, 2011, no. 2, pp. 12–18. (In Russ.)
  6. Chuchalin A.G. Bronchiectasis: clinical manifestations and diagnostic programmes. Pulmonologiya, 2005, no. 1, pp. 5–10. (In Russ.)
  7. Shmelev E.I., Kovalevskaya M.N., Ergeshov A.E., Chernousova L.N., Larionova E.E. Mycobacterioses in the pulmonologist’s practice: the status of the issue. Prakticheskaya pulmonologiya, 2016, no. 3, pp. 37–42. (In Russ.)
  8. Akram S.M., Bhimji S.S. Mycobacterium Chelonae. Source StatPearls [Internet], Treasure Island (FL): Stat­Pearls Publishing, 2017, May 16.
  9. Andrejak C., Thomsen V.O., Johansen I.S. et al. Non­tuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. J. Respir. Crit. Care Med., 2010, vol. 181, pp. 514–521.
  10. Argueta C., Yoder S., Holtzman A.E. et al. Isolation and identification of nontuberculous mycobacteria from foods as possible exposure sources. Food. Prot. 2000, vol. 63, no. 7, pp. 930–933.
  11. Cook J.L. Nontuberculous mycobacteria: opportunis­tic environmental pathogens for predisposed hosts. Br. Med. Bull., 2010, vol. 96, pp. 45–59.
  12. Dai J., Chen Y., Lauzardo M. Web-accessible data­base of hsp65 sequences from Mycobacterium refer­ence strains. Clin. Microbiol., 2011, vol. 49, no. 6, pp. 2296–2303.
  13. Daley C.L., Griffith D.E. Pulmonary non-tuberculous mycobacterial infections. J. Tuberc. Lung Dis., 2010, vol. 14, no. 6, pp. 665–671.
  14. David L., Heyman М. Diseases due to other myco­bacteria. Washington: American Public Health Asso­ciation, 2004, pp. 572–573.
  15. Falkinham J.O. Nontuberculous mycobacteria in the environment. Chest. Med., 2002, vol. 23, pp. 529–551.
  16. Falkinham J.O. Ecology of nontuberculous myco­bacteria – where do human infections come from? Respir. Crit. Care Med., 2013, vol. 34, pp. 95– 102.
  17. Good R.C. From the Center for Disease Control. Iso­lation of nontuberculous mycobacteria in the United States, 1979. Infect. Dis., 1980, vol. 142, pp. 779– 783.
  18. Griffith D.Е. Aksamit T., Brown-Elliott B.A., Catanza­ro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., Iseman M., Olivier K., Ruoss S., Fordham von Reyn C., Wallace R.J. Jr., Win­throp K. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous my­cobacterial diseases. Resp. Crit. Care Med., 2007, vol. 175, no. 4, pp. 367–416.
  19. Hatakeyama S., Ohama Y., Okazaki M. et al. Antimi­crobial susceptibility testing of rapidly growing my­cobacteria isolated in Japan. BMC Infect. Dis., 2017, vol. 17, no. 1, p. 197.
  20. Haworth C.S., Banks J., Capstick Т., Fisher A.J., Gor­such T., Laurenson I.F., Leitch A., Loebinger M.R., Mil­burn H.J., Nightingale M., Ormerod P., Shingadia D., Smith D., Whitehead N., Wilson R., Floto R.A. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, vol. 72, supp., pp. ii1–ii64.
  21. Ho N., Kurashima А., Morimoto К. Epidemiology of pulmonary nontuberculous mycobacterial dis­ease, Japan. Infect. Dis., 2016, vol. 22, no. 6, pp. 1116–1117.
  22. Hoefsloot W., van Ingen J., Andrejak C., Ange­by K., Bauriaud R., Bemer P., Beylis N., Boeree M.J., Cacho J., Chihota V., Chimara E., Churchyard G., Cias R., Daza R., Daley C.L., Dekhuijzen P.N., Domin­go D., Drobniewski F., Esteban J., Fauville-Dufaux M., Folkvardsen D.B., Gibbons N., Gómez-Mampaso E., Gonzalez R., Hoffmann H., Hsueh P.R., Indra A., Ja­gielski T., Jamieson F., Jankovic M., Jong E., Ke­ane J., Koh W.J., Lange B., Leao S., Macedo R., Mannsаker T., Marras T.K., Maugein J., Milburn N.J., Mlinkó T., Morcillo N., Morimoto K., Papaventsis D., Palenque E., Paez-Peña M., Piersimoni C., Pola­nová M., Rastogi N., Richter E., Ruiz-Serrano M.J., Silva A., da Silva M.P., Simsek H., van Soolingen D., Szabó N., Thomson R., Tórtola F.T., Tortoli E., Tot­ten S.E., Tyrrell G., Vasankari T., Villar M., Walkie­wicz R., Winthrop K.L., Wagner D. Nontuberculous Mycobacteria Network European Trials Group. The geographic diversity of nontuberculous mycobacte­ria isolated from pulmonary samples: an NTM-NET collaborative study. Respir. J., 2013, vol. 42, no. 6, pp. 1604–1613.
  23. Johnson M.M., Odell J.A. Nontuberculous myco­bacterial pulmonary infections. Thorac. Dis. 2014, vol. 6, no. 3, pp. 210–220.
  24. Jones M.M., Winthrop K.L., Nelson S.D. et al. Epide­miology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration. PLoS One, 2018, vol. 13, no. 6, p. e0197976.
  25. Kendall B., Winthrop K. Update on the epidemiology of pulmonary nontuberculous mycobacterial in­fections. Respir. Crit. Care Med. 2013, vol. 34, no. 1, pp. 87–94.
  26. Ko R.E., Moon S.M., Ahn S. et al. Changing epidemiology of nontuberculous mycobacterial lung diseases in a tertiary referral hospital in Korea between 2001 and 2015. Korean Med. Sci., 2018, vol. 33, no. 8, p. e65.
  27. Kwon Y.S., Koh W.J., Daley C.L. Treatment of Myco­bacterium avium Complex pulmonary disease. Respir. Dis. (Seoul), 2019, vol. 82, no. 1, pp. 15–26.
  28. Lim A.Y.H., Chotirmall S.H., Fok E.T.K. et al. Profiling non-tuberculous mycobacteria in an Asian setting: characteristics and clinical outcomes of hospitalized patients in Singapore. BMC Pulm. Med., 2018, vol. 18, no. 1. DOI: 10.1186/s12890‑018‑0637‑1
  29. Nichols G., Ford T., Bartram J., Dufour A., Portaels F. Pathogenic mycobacteria in water: A guide to public health consequences, monitoring and management. World Health Organization. Lon­don, IWA Publishing, 2004.
  30. Okamori S., Asakura T., Nishimura T. et al. Natural history of Mycobacterium fortuitum pulmonary infec­tion presenting with migratory infiltrates: a case re­port with microbiological analysis. BMC Infect. Dis., 2018, vol. 18, no. 1, pp. 2892–2899.
  31. Prevots D.R., Loddenkemper R., Sotgiu G., Miglio­ri G.B. Nontuberculous mycobacterial pulmonary dis­ease: an increasing burden with substantial costs. Respir. J., 2017, 49, no. 4: pii: 1700374.
  32. Ringshausen F.C., Wagner D., de Roux A. et al. Prev­alence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Infect. Dis., 2016, vol. 22, no. 6, pp. 1102–1105.
  33. Schoenfeld N., Haas W., Richter E., Bauer T., Boes L., Castell S., Hauer B., Magdorf K., Matthiessen W., Mauch H., Reuss A., Schenkel K., Ruesch-Gerdes S., Zabel P., Dalhoff K., Schaberg T., Loddenkemper R. Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respira­tory Society (DGP) for the Diagnosis and Treatment of Non-tuberculous Mycobacterioses. Pneumologie, 2016, vol. 70, no. 4, pp. 250–276.
  34. Shah N.M., Davidson J.A., Anderson L.F. et al. Pulmo­nary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007–2012. BMC Infect. Dis., 2016, vol. 16, p. 195.
  35. Tortoli E. Impact of genotypic studies on mycobacte­rial taxonomy: the new mycobacteria of the 1990s. Microbiol. Rev., 2003, vol. 16, pp. 319–354.
  36. Tortoli E. Microbiological features and clinical rele­vance of new species of the Genus Mycobacterium. Microbiol. Rev., 2014, vol. 27, no. 4, pp. 727– 752.
  37. Varghese В., Enani M.A., Shoukri M., et al. The first Saudi Arabian national inventory study revealed the upcoming challenges of highly diverse non-tubercu­lous mycobacterial diseases. PLoS One Negl. Trop. Dis., 2018, vol. 12, no. 5, p. e0006515. DOI: 10.1371/ journal.pntd.0006515.
  38. Yoon H.J., Choi H.Y., Ki M. Nontuberculosis mycobac­terial infections at a specialized tuberculosis treat­ment centre in the Republic of Korea. BMC Infect. Dis., 2017, vol. 17, no. 1, p. 432.
KEYWORDS:

mycobacteriosis, drug susceptibility, management, surgery, follow-up, treatment effectiveness.

FOR CORRESPONDENCE:

Moscow Research and Clinical Center for Tuberculosis Control of Moscow Government Department of Health

10, Stromynka St., 107014, Moscow, Russia

Lidiya D. Guntupova, Candidate of Medical Sciences, Phthisiologist, City Clinical and Diagnostic Center

Tel.: +7 (499) 161‑02‑30

Е-mail: guntupov@mail.ru

Sergey E. Borisov, Doctor of Medical Sciences, Professor, Deputy Director

Tel.: +7 (499) 268 50–10

Е-mail: sebarsik@gmail.com

THE COMPARISON OF RADIOLOGICAL FEATURES OF INFILTRATIVE AND DISSEMINATED PULMONARY TB IN DYNAMICS BASED ON COMPUTED TOMOGRAPHY AND PLAIN CHEST ROENTGENOGRAPHY RESULTS

Article 6.Page 50.
ARTICLE TITLE:

THE COMPARISON OF RADIOLOGICAL FEATURES OF INFILTRATIVE AND DISSEMINATED PULMONARY TB IN DYNAMICS BASED ON COMPUTED TOMOGRAPHY AND PLAIN CHEST ROENTGENOGRAPHY RESULTS

DOI: 10.7868/S2587667821010064

AUTORS:

Yatsukova A.V.1, Babaeva I.Yu.1, Shapolovsky V.S.2, Shapolovskaya A.S.2, Yatsukov A.V.1, Zhukova D.Yu.1

1 Kuban State Medical University, Krasnodar, Russia

2 Rostov State Medical University, Rostov-on-Don, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 01.09.2020

The analysis of the epidemic situation witnesses deferred detection of pulmonary TB due to low alertness for TB or diagnostic errors made by general practitioners.

Aim: to compare the dynamic course of infiltrative and disseminated pulmonary TB based on computed tomography (CT) and plain chest roentgenography results, evaluate features of radiological patterns of the diseases, and conduct a comparative assessment of informativity of the radiological methods in the disease dynamics. We conducted a retrospective analysis of 200 case records focusing on chest roentgenography and CT results in patients with infiltrative and disseminated pulmonary TB.

Conclusion. CT scanning allows discovering additional information about residual TB changes in the lungs with more accuracy than plain roentgenography.

REFERENCES:
  1. Babaeva I.Yu., Demikhova O.V., Kravchenko A.V., So­kol L.A. The immune status of patients with dissemi­nated pulmonary TB on different stages of HIV infec­tion. VICh-infektsiya i immunosupressiya, 2009, vol. 1, pp. 57–58. (In Russ.)
  2. Parpieva N.N., Safaev Kh.A., Yusupov N.E. Medical and social features of pulmonary TB patients residing in ecologically unfavourable Khorezm region. Pro­ceedings of the 8th Congress of phthisiologists and pulmonologists of Uzbekistan, 2015, p. 110. (In Russ.)
  3. Raviglione M.C., Korobitsyn A.A. End TB – the new WHO strategy in the SDG era, and the contributions from the Russian Federation. Tuberculosis and Lung Diseases, 2016, no. 11, pp. 7–17. (In Russ.)
  4. Respiratory medicine: guidelines. Ed. by A.G. Chuchalin. 2nd edition. Moscow, Litterra, 2017, vol. 1, p. 282. (In Russ.)
  5. Tashpulatova F.K., Sadykov A.S. The organization of pulmonary TB diagnosis at primary medical insti­tutions. Proceedings of the 8th Congress of phthisiologists and pulmonologists of Uzbekistan, 2015, pp. 43–49. (In Russ.)
  6. Tillyashaikhov M.N. The concept to improve TB care to the population of Uzbekistan (2011–2015). Proceedings of the 8th Congress of phthisiologists and pulmonologists of Uzbekistan, 2015, pp. 3–8. (In Russ.)
  7. Tyurin I.E., Neishtadt A.S., Cheremisin V.M. Comput­ed tomography in pulmonary TB. Petersburg, 1998, 235 p. (In Russ.)
  8. Phthisiology: national guidelines. Ed. by M.I. Perel­man. Moscow, GEOTAR-Media, 2010, 512 p. (In Russ.)
  9. Global tuberculosis report 2016. Geneva, World Health Organization, p. 179.
KEYWORDS:

pulmonary TB, chest computed tomography, plain chest roentgenography.

FOR CORRESPONDENCE:

Kuban State Medical University

4, Mitrofan Sedin St., 350063, Krasnodar, Krasnodarsky Krai, Russia

Alina V. Yatsukova, Assistant, Department of Infectious Diseases and Phthisiopulmonology

Tel.: +7 (918) 060‑60‑78

Е-mail: Dr.Yatsukova@yandex.ru

Irina Yu. Babaeva, Doctor of Medical Sciences, Professor, Department of Infectious Diseases and Phthisiopulmonology

Tel.: +7 (918) 191‑21‑74

Е-mail: Irenb74@mail.ru

Alexander V. Yatsukov, Assistant, Department of Radiology; Radiologist, Radiology Department, State Budgetary Healthcare Institution “Regional Clinical Hospital no. 2”, Krasnodar

Tel.: +7 (918) 060‑67‑89

Е-mail: Dr.Yatsukov@yandex.ru

Diana Yu. Zhukova, Resident Physician, Department of Infectious Diseases and Phthisiopulmonology

Теl.: +7 (918) 686‑11‑94

Е-mail: dianazhuk11@mail.ru

Rostov State Medical University

29, Nakhichevansky per., 344022, Rostov-on-Don, Rostov region, Russia

Vladimir S. Shapolovsky, Resident Physician, Department of Hematology and Transfusiology (with a course in clinical laboratory diagnostics, genetics and laboratory genetics); clinical laboratory diagnostics doctor

Tel: +7 (918) 948‑21‑61

E-mail: shapolovskiy@inbox.ru

Alexandra S. Shapolovskaya, Resident Physician, Department of Hematology and Transfusiology (with a course in clinical laboratory diagnostics, genetics and laboratory genetics); clinical laboratory diagnostics doctor

Tel.: +7 (918) 480‑45‑72

E-mail: ashapolovskaya@mail.ru

CHEMOTHERAPY IN SENIOR CHILDRENAND ADOLESCENTS WITH DRUG-RESISTANT PULMONARY TB: NEW CHALLENGES – NEW SOLUTIONS

Article 7.Page 58.
ARTICLE TITLE:

CHEMOTHERAPY IN SENIOR CHILDRENAND ADOLESCENTS WITH DRUG-RESISTANT PULMONARY TB: NEW CHALLENGES – NEW SOLUTIONS

DOI: 10.7868/S2587667821010076

AUTORS:

Panova L.V., Ovsyankina E.S.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 19.03.2020

Aim: To reduce the chemotherapy duration in senior children and adolescents with multi- and extensively drug resistant (MDR/XDR) pulmonary TB based on selective personalized chemotherapy regimens.

Materials and methods: In 2016–2019 we conducted cohort prospective studies, which enrolled patients aged 13–17 with different forms of pulmonary TB complicated by MDR/XDR.

Results. The development of personalized approaches justified: continuation of the main course of chemotherapy without return to the intensive phase after administration of a new regimen based on drug susceptibility testing (DST) results, effectiveness of shortened 12-month chemotherapy regimens in senior children and adolescents with pulmonary TB and MDR/XDR, the algorithm for developing shortened chemotherapy regimens for senior children and adolescents with pulmonary TB and MDR/XDR, the criteria of chemotherapy duration in senior children and adolescents with newly detected MDR/XDR in resection samples.

The article was prepared under research topic No. 0515-2019-0016 “Personalized approaches to pulmonary TB treatment in children and adolescents”.

REFERENCES:
  1. Clinical recommendations on tuberculosis in children. ROF, 2020, 54 p. (In Russ.) http://cr.rosminzdrav.ru/#!/ recomend/359.
  2. Nechaeva O.B. Tuberculosis in children in Russia. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 11, pp. 12–20. (In Russ.)
  3. Multidrug-resistant tuberculosis in children and adoles­cents in the WHO European Region. Expert opinion. WHO, 2020, 46 p. (In Russ.) https://apps.who.int/iris/bit­stream/handle/10665/331888/9789289054966-rus.pdf
  4. Groschel M.I., van den Boom M., Migliori G.B., Dara M. Prioritising children and adolescents in the tuber­culosis response of the WHO European Region. Eur. Respir. Rev., 2019, vol. 151, no. 28, p. 180106. DOI: 10.1183/16000617.0106-2018
  5. Roadmap towards ending TB in children and ado­lescents. Second edition. WHO, 2018, 32 p. https:// www.who.int/tb/publications/2018/tb-childhoodroad­map/en/
  6. Sandgren A., Cuevas L.E., Dara M., Gie R.P. Child­hood tuberculosis: progress requires an advocacy strategy now. Eur. Respir. J., 2012, vol. 40, no. 2, pp. 294–297. DOI: 10.1183/09031936.00187711
  7. WHO consolidated guidelines on drug-resistant tu­berculosis treatment. WHO, 2019, 104 p. www.who. int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
  8. WHO consolidated guidelines on tuberculosis, Module 4: Treatment – Drug-resistant tuberculosis treatment. WHO, 2020, 32 p. https://www.who.int/ publications/i/item/9789240007048
KEYWORDS:

TB, children and adolescents, MDR/XDR TB, shortened chemotherapy regimens, bedaquiline.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Ludmila V. Panova, Doctor of Medical Sciences, Leading Researcher, Child and Adolescent Department

Tel.: +7 (499) 785‑90‑05

E-mail: detstvocniit@mail.ru

Elena S. Ovsyankina, Doctor of Medical Sciences, Professor, Principal Researcher, Head of Child and Adolescent Department

Tel.: +7 (499) 785‑90‑05

E-mail: detstvocniit@mail.ru

THE OPPORTUNITIES OF CARDIOPROTECTIVE THERAPY: PATIENTS WITH TB AND CHRONIC OBSTRUCTIVEPULMONARY DISEASE IN FOCUS

Article 8.Page 65.
ARTICLE TITLE:

THE OPPORTUNITIES OF CARDIOPROTECTIVE THERAPY: PATIENTS WITH TB AND CHRONIC OBSTRUCTIVEPULMONARY DISEASE IN FOCUS

 DOI: 10.7868/S2587667821010088

AUTORS:

Bagisheva N.V.1, Mordyk A.V.1, Moiseeva M.V.1, Nesterova K.I.1, Nebesnaya E.Yu.1, Filipenko G.V.2, Aroyan A.R.1, 2, Batishcheva T.L.2, Andreeva I.A.2

1 Omsk State Medical University, Omsk, Russia

2 Clinical TB Dispensary, Omsk, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 19.09.2020

The article provides an assessment of the use of various combinations of cardioprotective drugs. The most effective therapy options for bronchopulmonary and cardiovascular comorbidities were identified. The study enrolled 80 patients on treatment for pulmonary TB with a history of chronic obstructive pulmonary disease (COPD) and signs of chronic heart failure (CHF) with preserved ejection fraction. The patients were divided into four groups based on therapy options. The comparative analysis involving clinical and instrumental parameters demonstrated the necessity to implement an individual approach in the selection of drug combinations due to polyvalent manifestations of the discussed comorbidities.

REFERENCES:
  1. Geltser B.I., Brodskaya T.A., Nevzorova V.A. Arterial stiffness and chronic obstructive pulmonary disease: pathophysiological interrelations and clinical signifi­cance. Terapevtichesky arkhiv, 2008, no. 11, pp. 89– 94. (In Russ.)
  2. Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. The role of aldosterone receptor antagonists in preven­tion and management of cardiovascular and renal diseases: the reality and prospects. Russian Medical Journal, 2014, no. 23, pp. 1689–1693. (In Russ.)
  3. Global tuberculosis control 2011. World Health Or­ganization. URL: https://apps.who.int/iris/bitstream/ handle/10665/44728/9789241564380_eng.pdf?se quence=1 (Date of referral: 02.07.2020).
  4. Danilyak I.G. Chronic obstructive pulmonary disease and ischemic heart disease. Pulmonologiya, 1992, no. 2, pp. 22–23. (In Russ.)
  5. Evdokimov V.V., Evdokimova A.G., Yushchuk E.N. The features of clinical and functional changes in pa­tients with CHF of ischemic genesis with concomi­tant COPD. Russian Medical Journal, 2019, no. 12, pp. 8–13. (In Russ.)
  6. Karpov Yu.A., Sorokin E.V. Mineralocorticoid recep­tor antagonists in chronic heart failure: indications for and selection of a drug based on modern knowledge. Atmosfera: Novosti kardiologii, 2015, no. 1, pp. 21–26. (In Russ.)
  7. Mareev V.Yu., Fomin I.V., Ageev F.T. Clinical recom­mendations of Russian Heart Failure Society – Rus­sian Society of Cardiology – Russian Scientific Medi­cal Society of Internal Medicine. Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagno­sis, prevention and treatment. Kardiologiya, 2018, vol. 58, no. 6S, pp. 8–158. (In Russ.)
  8. Mareev V.Yu., Fomin I.V., Ageev F.T. Clinical recommendations. Chronic heart failure. Serdechnaya nedostatochnost, 2017, vol. 18, no. 1, pp. 3–40. (In Russ.)
  9. Minushkina L.O., Zateishchikova A.A., Khotchenko­va N.V. The activity of the renin-aldosterone system and the features of the left ventricle structure and function in patients with arterial hypertension. Kardi­ologiya, 2000, no. 9, pp. 23–27. (In Russ.)
  10. Moiseeva M.V., Bagisheva N.V., Mordyk A.V., Iva­nova O.G., Ivanchenko A.A., Nazhmutdinova A.A., Shamsheva E.V., Mordyk D.I. Echocardiographic fea­tures of patients with chronic obstructive pulmo­nary disease and newly diagnosed TB. Vrach, 2019, vol. 30, no. 2, pp. 48–51. (In Russ.)
  11. Oshchepkova E.V., Lazareva N.V., Saltykova D.F., Tereshchenko S.N. The first results of the Russian register of chronic heart failure. Kardiologiya, 2015, vol. 55, no. 5, pp. 22–28. (In Russ.)
  12. Fomin I.V. Chronic heart failure in the Russian Fed­eration: what do we know and what do we have to do. Rossiysky kardiologichesky zhurnal, 2016, no. 8, pp. 7–13. (In Russ.)
  13. Campo G., Pavasini R., Malagu M. Chronic obstruc­tive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Drugs Ther., 2015, vol. 29, no. 2, pp. 147–155.
  14. Canepa M., Temporelli P.L., Rossi A. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI-HF Trial. Cardiology, 2017, vol. 136, no. 2, рр. 128–137.
  15. Hansell A.L., Walk J.A., Soriano J.B. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Respir. J., 2003, vol. 22, pp. 809–814.
  16. Hawkins N.M., Huang Z., Pieper K.S. Chronic obstruc­tive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction trial (VALIANT). Euro­pean Journal of heart failure, 2009, vol. 11, pp. 292– 298.
  17. Iqbal J., Parviz Y., Pitt B. et al. Selection of a miner­alocorticoid receptor antagonist for patients with hy­pertension or heart failure. J. Heart Fail., 2014, vol. 16, pp. 143–150.
  18. Owan T.E., Hodge D.O., Herges R.M., Jacobsen S.J., Roger V.L., Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine, 2006, vol. 355, no. 3, pp. 251–259.
  19. Wouters E.F., Creutzberg E.C., Schols A.M. Systemic effects in COPD. Chest, 2002, vol. 121, pp. 127–130.
KEYWORDS:

TB, chronic obstructive pulmonary disease, chronic heart failure, comorbidity, echocardiography, cardioprotective therapy

FOR CORRESPONDENCE:

Omsk State Medical University

12, Lenin St., 644099, Omsk, Russia

Natalia V. Bagisheva, Candidate of Medical Sciences, Docent, Department of Internal Diseases and Preclinical Therapy

Tel.: +7 (923) 672‑00‑20

E-mail: ppi100@mail.ru

Anna V. Mordyk, Doctor of Medical Sciences, Professor, Head, Department of Phthisiology, Phthisiosurgery and Infectious Diseases

Tel.: +7 (913) 649‑21‑19

E-mail: amordik@mail.ru

Marina V. Moiseeva, Candidate of Medical Sciences, Assistant, Department of Internal Diseases and Polyclinic Therapy

Tel.: +7 (913) 607‑43‑42

E-mail: lisnyak80@mail.ru

Klimentina I. Nesterova, Doctor of Medical Sciences, Professor, Otolaryngology Department

Tel.: +7 (904) 581‑91‑55

E-mail: nesterov_ivan@mail.ru

Ekaterina Yu. Nebesnaya, Resident Doctor, Department of Hospital Therapy, Endocrinology

Tel.: +7 (913) 689‑10‑59

E-mail: nebesnay_katya97@mail.ru

Clinical TB Dispensary

2, Tselinnaya St., 644058, Omsk, Russia

Anna R. Aroyan, Phthisiologist, Assistant, Department of Phthisiology, Phthisiosurgery and Infectious Diseases

Tel.: +7 (951) 426‑27‑39

E-mail: kptd_mail@minzdrav.omskportal.ru

Tatyana L. Batishcheva, Deputy Chief Physician for Treatment

Tel.: +7 (3812) 42‑44‑86

E-mail: kptd_mail@minzdrav.omskportal.ru

Irina A. Andreeva, Chief, Treatment and Diagnosis Department

Tel.: +7 (3812) 42‑22‑15

E-mail: kptd_mail@minzdrav.omskportal.ru

Galina V. Filipenko, Functional Diagnostician

Tel.: +7 (3812) 42‑22‑15

E-mail: kptd_mail@minzdrav.omskportal.ru

EFFECTIVENESS AND COST-EFFECTIVENESS OF MASS FLUOROGRAPHY SCREENING OF THE POPULATIONON THE EXAMPLE OF SAKHA (YAKUTIA) REPUBLIC

Article 9.Page 76.
ARTICLE TITLE:

EFFECTIVENESS AND COST-EFFECTIVENESS OF MASS FLUOROGRAPHY SCREENING OF THE POPULATIONON THE EXAMPLE OF SAKHA (YAKUTIA) REPUBLIC

DOI: 10.7868/S258766782101009X

AUTORS:

Кravchenko A.F., Shepeleva L.P.

Scientific Practical Phthisiology Center, Yakutsk, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 26.09.2020

We observed steady decline in the absolute number of new TB cases (by 29.04%, p < 0.001) and increase in the actual coverage of the population by fluorography screening (FS) (by 23.9%, p < 0.001) in Sakha Republic (Yakutia) in 2010–2019. Compared to the previous years, the population coverage by FS increased by 51.8% (p < 0.001). TB detection among the examined population increased by 23.05% (p < 0.001), while self-referrals to health facilities decreased by 39.5% (p < 0.05). The comparative analysis of the population coverage by routine FS approved by the Republican Ministry of Health and the actual coverage did not reveal significant differences (p > 0.05) for cases detected by either routine FS or at self-referrals to health facilities. The decrease rate of TB detection by FS was 46.5% (p < 0.001), while detection of different pathologies of the lungs (4540.50 ± 1306.91) was 14.3 times higher than TB detection (337.87 ± 11.85). There were nosignificant differences between TB (337.87 ± 11.85) and cancer (226.50 ± 15.24) detection by mass FS (p > 0.05). Generally, lung pathology detection (excluding TB) was 8.20 ± 2.80 cases per 1000 examinations, while TB detection was 0.57 ± 0.90 (t = 7.90; p < 0.001). Every year about 169.9 million rubles were spent on mass FS (excluding overhead costs); 4.7 million rubles were spent on TB diagnosis among cases with detected lung pathology. Thus, detection of one TB case (excluding overhead costs) cost 545.4 thousand rubles. Preventive fluorography screening demonstrated low cost-effectiveness but enabled to monitor the epidemiological situation of TB in general, take timely measures for its stabilization, and indirectly trace migration processes.

REFERENCES:
  1. Danilov A.N., Morozova T.I. The parallels between untimely detection of clinical pulmonary tuberculo­sis and fluorography screening of the population. Tuberculosis and Lung Diseases, 2015, no. 5, pp. 70– 71. (In Russ.)
  2. Gorbunov A.V., Kochetkova E.A. Some aspects of the fluorography service in Moscow and possible approaches to its reorganization. Problemy tuberku­lyoza i boleznei legkikh, 2003, vol. 80, no. 4, pp. 3–9. (In Russ.)
  3. Koretskaya N.M., Narkevich A.N. Newly detected pulmonary TB in individuals, who adhered to or de­faulted timely fluorography examinations in the ep­idemiologically unfavourable region. Tuberculosis and Lung Diseases, 2013, vol. 90, no. 9, pp. 21–24. (In Russ.)
  4. Kucherov A.L., Ilyicheva E.Yu. The ways to improve effectiveness of anti-TB activities and reduce costs of their implementation. Problemy tuberkulyoza i bolez­nei legkikh, 2003, vol. 80, no. 4, pp. 7–11. (In Russ.)
  5. Luginova E.F., Shepeleva L.P., Guryeva O.I. The trends of TB incidence in children in the Republic Sakha (Ya­kutia) for a 10-year period under the implementation of new diagnostic technologies. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 1, pp. 3–9. (In Russ.)
  6. Nechaeva O.B., Sterlikov S.A. The procedure for con­ducting preventive chest X-ray studies in the Russian Federation. Methodical recommendations. Moscow, CNIIOIZ, 2014, 28 p. (In Russ.)
  7. On the active detection of TB patients in the Sakha Republic (Yakutia): the resolution by the chief sani­tary doctor of the Sakha Republic (Yakutia) no. 5 of 24.07.2012. (In Russ.) [Electronic resource]. Mode of access: https://base.garant.ru/26733153/ (Date of re­ferral: 18.08.2020)
  8. On the procedure and terms for conducting preven­tive medical examinations of people for TB detec­tion. Order no. 124n of the Ministry of Health of the Russian Federation of 21.03.2017. (In Russ.) [Elec­tronic resource]. Mode of access: http://base.garant. ru/71688450/#friends (Date of referral: 18.08.2020)
  9. Kravchenko A.F., Vinokurova M.K., Luginova E.F. et al. The organization of TB detection in the population of the Sakha Republic (Yakutia): the instruction. Yakutsk, Scientific Practical Phthisiology Center, 2018, 39 p. (In Russ.) [Electronic resource] Mode of access: http:// ftiziatria.ykt.ru/wp-content/uploads/Инструкция-по-выявлению-ТБ.pdf (Date of referral: 18.08.2020)
  10. Resolution WHO 67.1. Global strategy and targets for tuberculosis prevention, care and control after 2015. The 67th session of the World Health Assembly, Geneva, 19–24 May 2014. The resolution and solu­tions. Annexes. (In Russ.) [Electronic resource] Mode of access: https://www.who.int/tb/post2015_strategy/ ru/ (Date of referral: 18.08.2020)
  11. Screening examinations in children and adoles­cents to detect TB infection. Methodical guidelines. All-Russian Public Organization “Russian Society of Phthisiatricians”, 2018, 39 p. (In Russ.) [Electron­ic resource] Mode of access: http://medradiology. moscow/d/1364488/d/skriningovoye_obsledovaniye_ detey_i_podrostkov_s_tselyu_2018.pdf (Date of re­ferral: 18.08.2020)
  12. Tyrylgin M.A. Tuberculosis. Epidemiology. Risk fac­tors. The basis for detection (on the model of Ya­kutia region). Yakutsk, Poligrafist, 1995, 191 p. (In Russ.)
  13. Tyrylgin M.A. The methods for the organization of selective active screening for TB in the Extreme North territories. Methodical recommendations. Mos­cow, 1991, 20 p. (In Russ.)
KEYWORDS:

TB, fluorography, mass fluorography screening, screening costs, cost per examination.

FOR CORRESPONDENCE:

Scientific Practical Phthisiology Center

93, P. Alekseev St., 677015, Yakutsk, Sakha Republic, Russia

Alexander F. Kravchenko, Doctor of Medical Sciences, Deputy Director for Medical Care in Ambulatory Settings

Tel.: +7 (924) 660‑99‑02

Е-mail: alex220560@yandex.ru

Larisa P. Shepeleva, Doctor of Medical Sciences, Head, Radiology Diagnostics Department

Tel.: +7 (914) 289‑94‑76

E-mail: shepelevalp@mail.ru

METHODS FOR THE IDENTIFICATION OF MYCOBACTERIUM SPECIES

Article 10.Page 87.
ARTICLE TITLE:

METHODS FOR THE IDENTIFICATION OF MYCOBACTERIUM SPECIES

DOI: 10.7868/S2587667821010106

AUTORS:

Larionova E.E., Andreevskaya S.N., Smirnova T.G., Sevastyanova E.V., Chernousova L.N.

 Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

 Submitted as of 03.01.2021

The article represents a review of methods used for the identification of Mycobacterium tuberculosis complex or non-tuberculous mycobacteria. We describe technical features of these methods. We also propose an algorithm of procedures for the identification of Mycobacterium species.

The article was prepared under research topic No. 0515-2019-0015: “The development of drug resistance of mycobacteria and somatic cells to TB drugs”.

REFERENCES:
  1. Sevastyanova E.V., Larionova E.E., Andrievskaya I.Yu. Microscopic detection of mycobacteria by Ziehl– Neelsen staining technique. Part 1. Smear prepa­ration and staining procedure. CTRI Bulletin, 2019, no. 1, pp. 100–108. (In Russ.)
  2. Sevastyanova E.V., Larionova E.E., Andrievskaya I.Yu. Microscopic detection of mycobacteria by Ziehl- Neelsen staining technique. Part 2. Sputum smear microscopy. CTRI Bulletin, 2019, no. 2, pp. 81–89. (In Russ.)
  3. Chernousova L.N., Puzanov V.A., Andreevskaya S.N., Smirnova T.G., Larionova E.E., Popov S.A. Laboratory diagnosis of TB. Educational materials for a refresh­er cycle. Ed. by V.V. Erokhin. Moscow, 2012, 707 p. (In Russ.)
  4. Chernousova L.N., Sevastyanova E.V., Larionova E.E., Smirnova T.G., Andreevskaya S.N., Popov S.A., Zhuravlev V.Yu., Puzanov V.A., Maryandyshev A.O., Vakhrusheva D.V., Kravchenko M.A., Safonova S.G., Vasilyeva I.A., Ergeshov A.E. Federal clinical recom­mendations for organization and implementation of microbiological and molecular genetic diagnosis of TB. Moscow, ROF, 2015, 35 p. (In Russ.)
  5. Abdeldaim G., Svensson E., Blomberg J., Her­rmann B. Duplex detection of the Mycobacterium tuberculosis complex and medically important non-tuberculosis mycobacteria by real-time PCR based on the rnpB gene. APMIS, 2016, vol. 124, no. 11, pp. 991–995.
  6. Brend A.J., Mugo D., Musyimi R. Scott J.A.G. et al. Performance of the MGIT TBc identification test and meta-analysis of MPT64 assays for identification of the Mycobacterium tuberculosis Complex in liquid culture. Journal of Clinical Microbiology, 2011, vol. 49, no. 12, pp. 4343–4346.
  7. Chen J.H., Cheng V.C., She K.K., Yam W.C., Yuen K.Y. Application of a dual target PCRhigh resolution melting (HRM) method for rapid nontuberculous myco­bacteria identification. Microbiol. Methods, 2017, vol. 132, pp. 1–3.
  8. European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic methods for the European Union, Stockholm, ECDC, 2016, 114 p.
  9. Favez G. Lung diseases due to atypical mycobacteria. Med. Wochenschr., 1975, vol. 105, no. 31, pp. 987–991.
  10. García-Martos P., García-Agudo L., Rodríguez-Jimé­nez M.J., Rodríguez-Iglesias M. Rapid identification of Mycobacterium tuberculosis complex from broth cultures by immunochromatographic assay. Esp. Quimioter., 2010, vol. 23, no. 4, pp. 206–209.
  11. Gomathi N.S., Devi S.M., Rvindra Sondalagere Lak­shmi, Selvakumar Nagamiah et al. Capilia test for identification of Mycobacterium tuberculosis in MGIT (TM)-positive cultures. The International Journal of Tuberculosis and Lung Disease, 2012, vol. 16, no. 6, pp. 788–792.
  12. Gopinath K., Singh S. Multiplex PCR assay for simul­taneous detection and differentiation of Mycobacte­rium tuberculosis, Mycobacterium avium complexes and other Mycobacterial species directly from clinical specimens. Appl. Microbiol., 2009, vol. 107, no. 2, pp. 425–435.
  13. Hong Y.J., Chung Y.H., Kim T.S., Song S.H., Park K.U., Yim J.J., Song J., Lee J.H., Kim E.C. Usefulness of three-channel multiplex real-time PCR and melting curve analysis for simultaneous detection and identi­fication of the Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Clin. Microbiol., 2011, vol. 49, pp. 3963–3966.
  14. Luna F.F.-A., Ruiz P., Gutierrez J., Casal M. Evaluation of the GenoType mycobacteria direct assay for de­tection of Mycobacterium tuberculosis complex and four atypical mycobacterial species in clinical sam­ples. Clin. Microbiol., 2006, vol. 44, pp. 3025–3027.
  15. Middlebrook G., Cohn M.L. Bacteriology of tuberculo­sis laboratory methods. J. Public Health Nations Health., 1958, vol. 48, no. 7, pp. 844–853.
  16. Richardson E.T., Samson D., Banaei N. Rapid identi­fication of Mycobacterium tuberculosis and nontu­berculous mycobacteria by multiplex, real-time PCR. Clin. Microbiol., 2009, vol. 47, pp. 1497–1502.
  17. Shrestha N.K., Tuohy M.J., Hall G.S., Reischl U., Gor­don S.M., Procop G.W. Detection and differentiation of Mycobacterium tuberculosis and nontuberculous mycobacterial isolates by real-time PCR. Clin. Micro­biol., 2003, vol. 41, pp. 5121–5126.
  18. Ustinova V.V., Smirnova T.G., Sochivko D.G., Var­lamov D.A., Larionova E.E., Andreevskaya S.N., An­drievskaya I.Yu., Kiseleva E.A., Chernousova L.N., Ergeshov A. New assay to diagnose and differentiate between Mycobacterium tuberculosis complex and nontuberculous mycobacteria. Tuberculosis, 2019, vol. 114, pp. 17–23.
  19. Global tuberculosis report. Geneva, WHO, 2019.
KEYWORDS:

mycobacteria, nutrient media, cultivation, identification, molecular biological methods.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Elena E. Larionova, Candidate of Biological Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: larionova_lena@mail.ru

Sofia N. Andreevskaya, Candidate of Medical Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: andsofia@mail.ru

Tatiana G. Smirnova, Candidate of Medical Sciences, Head, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: s_tatka@mail.ru

Elina V. Sevastyanova, Doctor of Biological Sciences, Leading Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: elinasev@yandex.ru

Larisa N. Chernousova, Doctor of Biological Sciences, Professor, Principal Researcher, Microbiology Department

Tel.: +7 (499) 785‑90‑91

Е-mail: lchernousova@mail.ru